RSS-Feed abonnieren
DOI: 10.1055/s-2005-865082
© Georg Thieme Verlag Stuttgart · New York
Die systolische Herzinsuffizienz des Älteren
Systolic heart failure in the elderlyPublikationsverlauf
eingereicht: 18.1.2005
akzeptiert: 2.3.2005
Publikationsdatum:
18. März 2005 (online)

Zusammenfassung
Mit zunehmendem Lebensalter kommt es sowohl im Herzen als auch im Gefäßsystem zu strukturellen Veränderungen, die die Entwicklung einer Herzinsuffizienz im Alter begünstigen. Eine vermehrte Steifheit der Arterienwand führt dabei zu einer Zunahme des systolischen arteriellen Drucks und der Pulswellengeschwindigkeit. Die resultierende Nachlasterhöhung des Herzens trägt zur Myokardhypertrophie und zur neuroendokrinen Aktivierung im Alter bei. Auf molekularer Ebene finden sich im alternden Herzen Veränderungen, die auch bei manifester Herzinsuffizienz nachgewiesen werden können. Dies gilt insbesondere für das sympathische Nervensystem. Die Therapie einer systolischen Herzinsuffizienz bei älteren Patienten unterscheidet sich nicht von der jüngerer Patienten. Sämtliche Substanzen, die bei jungen Menschen mit chronischer Herzinsuffizienz die Prognose verbessern, sind auch im hohen Alter indiziert. Dies gilt für ACE-Hemmer bzw. Angiotensin-Rezeptorantagonisten ebenso wie für Betablocker und Aldosteronantagonisten. Komorbiditäten sowie eine veränderte Pharmakokinetik und Pharmakodynamik erfordern jedoch oftmals eine langsamere Therapieeinleitung, eine individuelle Dosisanpassung sowie eine engmaschigere Überwachung älterer Patienten
Summary
Aging is associated with changes in cardiac and vascular structure, promoting the development of heart failure. An increase in vascular stiffness leads to an increase of systolic arterial pressure and pulse wave velocity. This augments the afterload of the heart, which contributes to cardiac hypertrophy and neuroendocrine activation in the elderly. On the molecular level the age-associated changes in the sympathetic nervous system are similar to alterations that can be found in congestive heart failure. Therapy of systolic heart failure does not differ between the elderly and younger patients. All drugs which have shown to improve the prognosis of younger patients are indicated in the elderly as well. This holds true for ACE-inhibitors or angiotensin receptor antagonists, betablockers and aldosterone antagonists. However, comorbidities as well as changes in the pharmacokinetics and pharmacodynamics might require a cautious initiation of the therapy, an individual adjustment of the dosage and a thoroughly monitoring of the elderly patients.
Literatur
- 1
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators .
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction
with clinical evidence of heart failure.
Lancet.
1993;
342
821-828
MissingFormLabel
- 2
The Digitalis Investigation Group .
The effect of digoxin on mortality and morbidity in patients with heart failure.
N Engl J Med.
1997;
336
525-533
MissingFormLabel
- 3
Böhm M, Dorner H, Htun P, Lensche H, Platt D, Erdmann E.
Effects of exercise on myocardial adenylate cyclase and Gi alpha expression in senescence.
Am J Physiol.
1993;
264
H805-814
MissingFormLabel
- 4
Casale P N, Devereux R B, Milner M. et al .
Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular
morbid events in hypertensive men.
Ann Intern Med.
1986;
105
173-178
MissingFormLabel
- 5
Castellano M, Böhm M.
The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive
heart disease.
Hypertension.
1997;
29
715-722
MissingFormLabel
- 6
Cohn J N, Tognoni G.
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart
failure.
N Engl J Med.
2001;
345
1667-1675
MissingFormLabel
- 7
Deedwania P C, Gottlieb S, Ghali J K, Waagstein F, Wikstrand J C.
Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL
in elderly patients with heart failure.
Eur Heart J.
2004;
25
1300-1309
MissingFormLabel
- 8
Erdmann E, Lechat P, Verkenne P, Wiemann H.
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk
patient groups with chronic heart failure.
Eur J Heart Fail.
2001;
3
469-479
MissingFormLabel
- 9
Esler M D, Thompson J M, Kaye D M. et al .
Effects of aging on the responsiveness of the human cardiac sympathetic nerves to
stressors.
Circulation.
1995;
91
351-358
MissingFormLabel
- 10
Flather M D, Shibata M C, Coats A J. et al .
Randomised Trial to Determine the Effect of Nebivolol on Mortality and Cardiovascular
Hospital Admission in Elderly Patients with Heart Failure (SENIORS).
Eur Heart J.
2005;
26
215-225
MissingFormLabel
- 11
Flather M D, Yusuf S, Kober L. et al. ACE-Inhibitor Myocardial Infarction Collaborative Group .
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular
dysfunction: a systematic overview of data from individual patients.
Lancet.
2000;
355
1575-1581
MissingFormLabel
- 12
Fleg J L, O’Connor F, Gerstenblith G. et al .
Impact of age on the cardiovascular response to dynamic upright exercise in healthy
men and women.
J Appl Physiol.
1995;
78
890-900
MissingFormLabel
- 13
Gambassi G, Forman D E, Lapane K L. et al. The SAGE Study Group .
Management of heart failure among very old persons living in long-term care: has the
voice of trials spread?.
Am Heart J.
2000;
139
85-93
MissingFormLabel
- 14
Garg R, Yusuf S. Collaborative Group on ACE Inhibitor Trials .
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality
and morbidity in patients with heart failure.
Jama.
1995;
273
1450-1456
MissingFormLabel
- 15
Hunt S A, Baker D W, Chin M H. et al .
ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the
Adult: Executive Summary A Report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines.
Circulation.
2001;
104
2996-3007
MissingFormLabel
- 16
Juurlink D N, Mamdani M M, Lee D S. et al .
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
N Engl J Med.
2004;
351
543-551
MissingFormLabel
- 17
Kannel W B, Belanger A J.
Epidemiology of heart failure.
Am Heart J.
1991;
121
951-957
MissingFormLabel
- 18
Kaye D M, Lefkovits J, Jennings G L, Bergin P, Broughton A, Esler M D.
Adverse consequences of high sympathetic nervous activity in the failing human heart.
J Am Coll Cardiol.
1995;
26
1257-1263
MissingFormLabel
- 19
Kitzman D W, Gardin J M, Gottdiener J S. et al .
Importance of heart failure with preserved systolic function in patients > or = 65
years of age. CHS Research Group. Cardiovascular Health Study.
Am J Cardiol.
2001;
87
413-419
MissingFormLabel
- 20
Koren M J, Devereux R B, Casale P N, Savage D D, Laragh J H.
Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated
essential hypertension.
Ann Intern Med.
1991;
114
345-352
MissingFormLabel
- 21
Lakatta E G, Levy D.
Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises:
Part I: aging arteries: a „set up” for vascular disease.
Circulation.
2003;
107
139-146
MissingFormLabel
- 22
Lakatta E G, Levy D.
Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises:
Part II: the aging heart in health: links to heart disease.
Circulation.
2003;
107
346-354
MissingFormLabel
- 23
Levy D, Savage D D, Garrison R J, Anderson K M, Kannel W B, Castelli W P.
Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart
Study.
Am J Cardiol.
1987;
59
956-960
MissingFormLabel
- 24
Masoudi F A, Havranek E P, Wolfe P. et al .
Most hospitalized older persons do not meet the enrollment criteria for clinical trials
in heart failure.
Am Heart J.
2003;
146
250-257
MissingFormLabel
- 25
McCullough P A, Hollander J E, Nowak R M. et al .
Uncovering heart failure in patients with a history of pulmonary disease: rationale
for the early use of B-type natriuretic peptide in the emergency department.
Acad Emerg Med.
2003;
10
198-204
MissingFormLabel
- 26
Packer M, Coats A J, Fowler M B. et al .
Effect of carvedilol on survival in severe chronic heart failure.
N Engl J Med.
2001;
344
1651-1658
MissingFormLabel
- 27
Packer M, Cohn J N, Abrahem W T. et al .
Consensus recommendations for the management of chronic heart failure.
Am J Cardiol.
1999;
83
1A-38A
MissingFormLabel
- 28
Packer M, Poole-Wilson P A, Armstrong P W. et al. ATLAS Study Group .
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor,
lisinopril, on morbidity and mortality in chronic heart failure.
Circulation.
1999;
100
2312-2318
MissingFormLabel
- 29
Pfeffer M A, Swedberg K, Granger C B. et al .
Effects of candesartan on mortality and morbidity in patients with chronic heart failure:
the CHARM-Overall programme.
Lancet.
2003;
362
759-766
MissingFormLabel
- 30
Philbin E F, Rocco T A, Lindenmuth N W, Ulrich K, Jenkins P L.
Clinical outcomes in heart failure: report from a community hospital-based registry.
Am J Med.
1999;
107
549-555
MissingFormLabel
- 31
Pitt B, Poole-Wilson P A, Segal R. et al .
Effect of losartan compared with captopril on mortality in patients with symptomatic
heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II.
Lancet.
2000;
355
1582-1587
MissingFormLabel
- 32
Pitt B, Remme W, Zannad F. et al .
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction
after myocardial infarction.
N Engl J Med.
2003;
348
1309-1321
MissingFormLabel
- 33
Pitt B, Segal R, Martinez F A. et al .
Randomised trial of losartan versus captopril in patients over 65 with heart failure
(Evaluation of Losartan in the Elderly Study, ELITE).
Lancet.
1997;
349
747-752
MissingFormLabel
- 34
Pitt B, Zannad F, Remme W J. et al. Randomized Aldactone Evaluation Study Investigators .
The effect of spironolactone on morbidity and mortality in patients with severe heart
failure.
N Engl J Med.
1999;
341
709-717
MissingFormLabel
- 35
Rathore S S, Curtis J P, Wang Y, Bristow M R, Krumholz H M.
Association of serum digoxin concentration and outcomes in patients with heart failure.
JAMA.
2003;
289
871-878
MissingFormLabel
- 36
Rich M W.
Management of heart failure in the elderly.
Heart Fail Rev.
2002;
7
89-97
MissingFormLabel
- 37
Rodeheffer R J, Gerstenblith G, Becker L C, Fleg J L, Weisfeldt M L, Lakatta E G.
Exercise cardiac output is maintained with advancing age in healthy human subjects:
cardiac dilatation and increased stroke volume compensate for a diminished heart rate.
Circulation.
1984;
69
203-213
MissingFormLabel
- 38
Xiao R P, Tomhave E D, Wang D J. et al .
Age-associated reductions in cardiac beta1- and beta2-adrenergic responses without
changes in inhibitory G proteins or receptor kinases.
J Clin Invest.
1998;
101
1273-1282
MissingFormLabel
- 39
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med.
2000;
342
145-153
MissingFormLabel
Dr. Heiko Kilter
Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes
66421 Homburg/Saar
Telefon: 06841/1623000
Fax: 06841/1623434
eMail: kilter@med-in.uni-sb.de